Matchpoint Therapeutics
Andre Turenne's work experience includes serving as the President and CEO of Matchpoint Therapeutics since October 2021. Before this, they were the President and CEO of Voyager Therapeutics, Inc. from July 2018 to June 2021. Prior to that, they held various roles at Sanofi, including Senior Vice President, Global Head of Business Development & Licensing from December 2015 to March 2018, Managing Director for Australia and New Zealand in 2015, and Head of Strategy & Business Development from October 2012 to December 2014.
Andre Turenne attended Kalamazoo College for an unspecified period of time, and later, from 2004 to 2006, they studied at The Tuck School of Business at Dartmouth. No specific degree or field of study is mentioned in the provided information.
This person is not in any offices
Matchpoint Therapeutics
Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning, and covalent chemistry libraryevolution. Matchpoint has an emerging pipeline of novel covalent medicines, initially focused on immunology.